Switching to an alternative recombinant erythropoietin agent in patients with myelodysplastic syndromes: a second honeymoon?

Br J Haematol. 2021 Nov;195(4):e147-e150. doi: 10.1111/bjh.17722. Epub 2021 Jul 26.

Authors

Bruno Fattizzo^{1

2}, Lorenzo Rizzo³, Juri Alessandro Giannotta¹, Federico Mazzon³, Nicola Cecchi², Claudia Frangi³, Wilma Barcellini¹, Marta Riva³

Affiliations

¹ Hematology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.
² Department of Oncology and Oncohematology, University of Milan, Milan, Italy.
³ Department of Hematology and Oncology, Niguarda Cancer Center, ASST Ospedale Niguarda, Milan, Italy.

PMID: 34312838
DOI: 10.1111/bjh.17722

No abstract available

Keywords: erythropoietin; myelodysplastic syndromes; transfusion.

Publication types

Letter

MeSH terms

Aged
Aged, 80 and over
Biosimilar Pharmaceuticals / therapeutic use
Blood Transfusion
Darbepoetin alfa / therapeutic use*
Drug Substitution
Epoetin Alfa / therapeutic use*
Erythropoietin / therapeutic use*
Female
Ferritins / blood
Follow-Up Studies
Humans
Male
Middle Aged
Myelodysplastic Syndromes / drug therapy*
Myelodysplastic Syndromes / therapy
Quality of Life
Recombinant Proteins / therapeutic use

Substances

Biosimilar Pharmaceuticals
Recombinant Proteins
epoetin beta
Erythropoietin
Darbepoetin alfa
Epoetin Alfa
Ferritins